2016 Project Fund Program


Following the release of the Draft Sector Competitiveness Plan in July 2016, MTPConnect's judging panel selected 14 initial projects to receive funding of $7.4 million over the following two years, with matched sector funding of approximately $32 million.

The 2016 round of the MTPConnect Project Fund Program provided $7.4 million of funding for 14 national projects in the medtech, biotech and pharmaceutical (MTP) sector, that could leverage as much as $32 million in industry partner funds. The selected projects are set to deliver results on a national scale, have sector-wide impact, and are aligned with MTPConnect’s Sector Growth Priorities as defined in its draft Sector Competitiveness Plan. View the 2016 projects below and in the right-hand menu.

Expressions of Interest for the 2017 Project Fund Program will open on 3 July 2017. Sign up as a Network Affiliate to stay up to date for your chance to collaborate and help take the MTP sector to the next level.


Murdoch Children’s Research Institute

Consortium members: Fidere Group, AusBiotech, Planet Innovation, Novartis Pharmaceuticals, Konica Minolta, Curve Tomorrow, RMIT University, GP2U, Royal Children’s Hospital, HealthXL, Bright Arena

A National Digital Health Initiative to create an integrated ecosystem for the development and commercialisation of evidence-based digital health products.


Monash University with CSIRO

Consortium members: CSIRO, with letters of support from eight additional organisations

Aiming to upgrade the CSIRO (Clayton) protein production platform to human GMP capability for pilot-scale (<=200L) for a variety of expression systems (mammalian/yeast/ bacterial) as well as scale-up of cells.


Monash University

Consortium members: CSIRO, CCRM, Cell Therapies, St Vincent's Institute of Medical Research, AusBiotech Ltd

CCRM Australia, an Australian hub of Canada’s Commercialization Centre for Regenerative Medicine (CCRM) will support the development of foundational technologies to accelerate the commercialisation of regenerative medicine products and therapies.


Cancer Therapeutics CRC Pty Ltd (CTx)

Consortium members: UniQuest/Queensland Emory Drug Discovery Initiative (QEDDI), Monash Institute of Pharmaceutical Sciences (MIPS), Walter + Eliza Hall Institute (WEHI), Children's Cancer Institute (CCI)

Build on a national framework to provide Australian drug discovery organisations access to a comprehensive Hit ID platform that includes: a fit for purpose drug discovery library (up to 450,000 compounds); an ultra-high throughput screening facility; fragment based drug design capability; and a state of the art software platform for in silico drug discovery.


Clinical Oncology Society of Australia (COSA)

Consortium members: Rare Cancers Australia, Cancer Voices Australia, Australian Institute of Tropical Health and Medicine (AITHM), The Garvan Institute of Medical Research, The Walter + Eliza Hall Institute of Medical Research (WEHI), Icon Group c/- Icon Consolidated Holdings P/L, St John of God Hospital, Medicines Australia, AbbVie Pty Ltd, Janssen, Novartis Pharmaceuticals Australia Pty Ltd, Pfizer Australia Pty Ltd

The Clinical Oncology Society of Australia has developed a national guide for implementation of the Australasian Tele‐Trial Model in consultation with clinical trial sponsors, clinicians, health administrators and regulatory bodies. This project will implement a feasible and effective tele‐health strategy to increase access to clinical trials closer to the participant’s homes, while at the same time ensuring the proper conduct of cancer clinical trials.


MTPConnect has also set funds aside to create a specific clinical trial initiative which will be further scoped with the sector in the coming weeks.